Key stats
About iShares Genomics Immunology and Healthcare ETF
Home page
Inception date
Jun 11, 2019
Structure
Open-Ended Fund
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a Relationship Keyword Score to each of the eligible companies using the FactSet Supply Chain Relationships database in search for keywords related to Genomics and Immuno Biopharmaceutical products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.